Physician profile
Bradley Templeton
NPI 1093890097
$2,610.01
in general payments reported to CMS, 2019-2025
33 companies · $17.46 in 2025
The $17.46 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $730 · 2021: $644 · 2022: $393 · 2025: $17.46.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $543.30 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $233.16 | 2019-2021 | |
| Allergan, INC. | $168.85 | 2019-2020 | |
| Glaxosmithkline, LLC. | $148.89 | 2019-2021 | |
| Abbvie INC. | $120.28 | 2019-2022 | |
| Lilly USA, LLC | $115.56 | 2020-2022 | |
| Pfizer INC. | $113.39 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $109.44 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $104.85 | 2019-2022 | |
| Bausch Health US, LLC | $94.41 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.11 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $78.41 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.27 | 2019-2022 | |
| Amarin Pharma, INC. | $69.49 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $64.16 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $61.98 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $58.79 | 2021 | |
| Currax Pharmaceuticals LLC | $43.84 | 2021 | |
| Dexcom, INC. | $42.53 | 2022 | |
| Avion Pharmaceuticals | $33.20 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $29.04 | 2019-2020 | |
| Astellas Pharma US INC | $26.06 | 2021-2022 | |
| Corcept Therapeutics | $19.30 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $18.99 | 2022 | |
| Tris Pharma INC | $17.83 | 2019 | |
| Medtronic, INC. | $17.46 | 2025 | Inceptiv |
| Eisai INC. | $17.05 | 2020 | |
| Lundbeck LLC | $16.74 | 2022 | |
| Mylan Specialty L.P. | $15.77 | 2019 | |
| Becton, Dickinson and Company | $15.10 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.57 | 2022 | |
| Amgen INC. | $13.59 | 2020 | |
| Genentech USA, INC. | $12.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Templeton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.